DFTX.US Definium Therapeutics, Inc.
- Market cap
- USD 4.39B
- P/E
- -
- P/B
- 4.67x
- ROE
- -39.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DFTX.US undervalued?
Graham numberThe Graham number of Definium Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Definium Therapeutics, Inc. fundamental analysis
No fundamental analysis for Definium Therapeutics, Inc. yet.
Definium Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was form…
Full company profileDefinium Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Definium Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -5.50K | -6.68K | -6.68K | - | - | - | -3.16M | -527K | - | - |
| Operating Income | -111K | -1.24M | -862K | -468K | -33.0M | -93.9M | -66.3M | -93.9M | -104M | -166M | -275M |
| EBITDA | -111K | -1.51M | -851K | -1.11M | -33.2M | -91.2M | -52.1M | -92.6M | -106M | -178M | -377M |
| Net Income | -180K | -1.23M | -858K | -1.12M | -34.1M | -93.0M | -56.8M | -95.7M | -109M | -184M | -383M |
| EPS | -2.24 | -4.85 | -2.74 | -2.94 | -1.92 | -3.40 | -1.84 | -2.44 | -0.15 | -2.06 | -2.79 |
| Balance Sheet | |||||||||||
| Total Assets | 203K | 4.03M | 3.53M | 2.94M | 81.5M | 164M | 170M | 125M | 302M | 440M | 1.07B |
| Total Liabilities | 75.5K | 80.4K | 8.23K | 199K | 5.65M | 12.3M | 19.1M | 46.4M | 60.7M | 108M | 106M |
| Shareholders' Equity | 127K | 3.95M | 3.52M | 2.74M | 75.9M | 152M | 151M | 78.1M | 241M | 332M | 968M |
| Cash & Short-term Investments | 129K | 1.69M | 155K | 17.9K | 80.1M | 134M | 142M | 99.7M | 274M | 412M | 1.05B |
| Total Debt | - | 15.7K | - | - | - | - | 72.0K | 14.1M | 21.9M | - | 36.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -26.6K | -666K | -722K | -208K | -23.6M | -45.8M | -50.1M | -64.4M | -79.1M | -132M | -198M |
| Capital Expenditure | 30.1K | 2.15M | 1.04M | 313K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -56.7K | -2.82M | -1.77M | -522K | -23.6M | -45.8M | -50.1M | -64.4M | -79.1M | -132M | -198M |
| Ratios | |||||||||||
| ROE | -141.3% | -31.1% | -24.3% | -40.8% | -44.9% | -61.3% | -37.6% | -122.5% | -45.0% | -55.3% | -39.5% |
| ROA | -88.7% | -30.5% | -24.3% | -38.0% | -41.8% | -56.7% | -33.4% | -76.9% | -36.0% | -41.8% | -35.6% |
| Debt to Equity | - | 0.00x | - | - | - | - | 0.00x | 0.18x | 0.09x | - | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Definium Therapeutics, Inc. dividends
Definium Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Aug 29, 2022.
Who owns Definium Therapeutics, Inc.
- Insiders 3.20%
- Institutions 92.90%
- Public & others 3.90%
- Shares outstanding 137M
- Free float 128M
Top funds holding DFTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 10.3M | 7.63% | +33.35% | Sep 2026 |
| iShares Russell 2000 ETF | 3.17M | 2.36% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.42M | 1.06% | +0.14% | Aug 2026 |
| Vanguard Health Care Inv | 1.27M | 0.94% | +71.19% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 1.18M | 0.88% | -0.38% | Oct 2026 |
| T. Rowe Price New Horizons | 1.13M | 0.84% | -7.02% | Sep 2026 |
| iShares Biotechnology ETF | 996K | 0.74% | -0.49% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 901K | 0.67% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 873K | 0.65% | +10.52% | Jun 2026 |
| Candriam Eqs L Biotech C USD Cap | 791K | 0.59% | -18.53% | Apr 2026 |
| Fidelity Small Cap Growth | 779K | 0.58% | 0.00% | Aug 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 772K | 0.57% | 0.00% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 766K | 0.57% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 745K | 0.55% | +9.76% | Sep 2026 |
| Polar Capital Biotech S Inc | 735K | 0.55% | 0.00% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 731K | 0.54% | +8.05% | Aug 2026 |
| Vanguard Russell 2000 ETF | 727K | 0.54% | -2.79% | Sep 2026 |
| T. Rowe Price Health Sciences | 721K | 0.54% | -25.12% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 713K | 0.53% | +0.24% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 710K | 0.53% | +3.47% | Jun 2026 |
Top institutions holding DFTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 11.2M | 8.36% | +32.46% | Jun 2026 |
| venBio Select Advisor LLC | 7.19M | 5.35% | +43.78% | Jun 2026 |
| Driehaus Capital Management LLC | 6.85M | 5.09% | +15.79% | Jun 2026 |
| Jupiter Topco LLC | 5.62M | 4.18% | 0.00% | Jun 2026 |
| Capital World Investors | 5.37M | 3.99% | 0.00% | Jun 2026 |
| FMR Inc | 4.75M | 3.54% | +162.65% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.65M | 3.46% | +6,545.67% | Jun 2026 |
| Geode Capital Management, LLC | 3.64M | 2.71% | +46.06% | Jun 2026 |
| State Street Corp | 3.07M | 2.28% | +24.01% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 2.96M | 2.21% | 0.00% | Jun 2026 |
| Octagon Capital Advisors LP | 2.95M | 2.20% | +20.90% | Jun 2026 |
| Wellington Management Company LLP | 2.95M | 2.20% | +126.08% | Jun 2026 |
| Deep Track Capital, LP | 2.75M | 2.05% | -8.33% | Jun 2026 |
| COMMODORE CAPITAL LP | 2.00M | 1.49% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 1.80M | 1.34% | +1,866.44% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.80M | 1.34% | +7.49% | Jun 2026 |
| Citadel Advisors Llc | 1.69M | 1.26% | +26.63% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.65M | 1.23% | +88.90% | Jun 2026 |
| RA Capital Management, LLC | 1.50M | 1.12% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.49M | 1.11% | +35.50% | Jun 2026 |
Definium Therapeutics, Inc. company profile
- Company name
- Definium Therapeutics, Inc.
- Ticker
- DFTX.US
- ISIN
- CA24477V1058
- Exchange
- USA Stocks
- Listed since
- Jul 11, 2022
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 105
- Fiscal year end
- December
- Address
- One World Trade Center, New York, NY, United States, 10007
- Phone
- 212 220 6633
- Website
- definiumtx.com
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Definium Therapeutics, Inc. management
10- Mr. Robert BarrowCEO & Director · born 1989
- Ms. Brandi L. Roberts CPA, M.B.A.Chief Financial Officer · born 1974
- Dr. Daniel Rollings Karlin M.A., M.D.Chief Medical Officer · born 1980
- Dr. Scott M. Freeman M.D.Co-Founder & Clinical Advisor · born 1957
- Mr. Leonard LatchmanCo-Founder
- Mr. Peter MackSenior Vice President of Pharmaceutical Development & Operations
- Ms. Gitanjali Jain OgawaVP & Head of Investor Relations
- Mr. Mark R. Sullivan J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Ms. Beth CalitriVice President of Corporate Communications
- Ms. Stephanie Fagan M.S.Chief Corporate Affairs Officer